U.S. Reclassifies Marijuana as Schedule III Substance Under New Order

In Brief

The reclassification of marijuana may affect medical access, regulation, and the legal status of cannabis products nationwide.

Key Facts

• A new order moves marijuana from Schedule I to Schedule III classification.
• The change places state-licensed medical marijuana alongside substances like ketamine and testosterone.
• Acting U.S. Attorney General Todd Blanche signed the order rescheduling FDA-approved and state-licensed medical cannabis products.
• The announcement led to both celebration and confusion among industry observers.
• Marijuana stocks sold off following the rescheduling news.

What Happened

U.S. authorities issued an order reclassifying marijuana from Schedule I to Schedule III, affecting state-licensed and FDA-approved medical cannabis products.

Why It Matters

This change could alter how marijuana is regulated and accessed for medical use, potentially impacting legal frameworks and the cannabis industry.

What's Next

Observers are watching for regulatory adjustments, market responses, and further guidance on how the new classification will be implemented.